Shared Care Guidelines. In partnership with Acute Trust & PCTs. SIROLIMUS In renal transplant. August 2016
|
|
- Nicholas Webster
- 5 years ago
- Views:
Transcription
1 Shared Care Guidelines In partnership with Acute Trust & PCTs SIROLIMUS In renal transplant August 2016 Page 0 of 12
2 Table of Contents Introduction 2 Licensing 2 Referral 2 Initiation and maintenance of therapy 3 Administration 3 Supply 3 Prescribing 3 Adverse effects 4 Contraindication 4 Drug interactions 4 Monitoring 5 Area of responsibility for the sharing of care 5 Responsibilities of the Hospital 6 Responsibilities of the GP 6 Overdose 6 Availability of Consultant and senior hospital staff 7 Additional sources of advice 7 Key points summary Sirolimus inhibits both B and T cell activation leading to suppression of immune and rejection responses. The pharmacological action of sirolimus appears to differ to that of tacrolimus and ciclosporin. Tablets should be protected from light Oral solution should be kept in the fridge but may be kept at room temperature for up to 24 hours if necessary Oral solution should be mixed with at least 60ml water or orange juice immediately before taking, refill container with at least 120ml and drink immediately to ensure total dose received. Do not mix with any other liquids Page 1 of 12
3 Introduction Mid Essex Hospitals Services NHS Trust (MEHT) and the local PCTs have agreed that sirolimus is suitable for shared-care: Prescribing status RED: For all new patients prescribing to remain with secondary care. Prescribing status AMBER: SHARED CARE for existing patients only The objectives of these guidelines are: To provide impartial information to GPs and community pharmacists who may not have previous experience of this drug To define the procedure for referral of the patient from the hospital to the GP To define the aspects of care for which the hospital and GP are responsible To define the support available from the hospital To establish lines of communication between GPs, Consultants and senior hospital staff Contributors to these guidelines are: Dr A Ali Dr S Abeygunasekara Dr AY Chan Sarah Cox Renal Pharmacist Author: Clare Drain, Medicines Information & Education & Training manager Licensing Sirolimus is licensed for immunosuppression in cases of ciclosporin or tacrolimus nephrotoxicity and for primary immunosuppression in kidney allograft recipients with low to medium immunological risk. Referral of patients The patient will be assessed by a specialist, and the decision to commence sirolimus therapy made. Once stable the specialist will invite the GP to undertake shared care. Page 2 of 12
4 Initiation and maintenance of therapy Medication history is checked to ensure there are no contra-indications to sirolimus therapy Blood levels of sirolimus will be monitored Full blood counts and coagulation tests (including U&Es) Liver function tests Initial cholesterol level monitoring Administration/dosage Sirolimus should be taken at the same time each day in relation to food. Sirolimus may be added to immunosuppressive therapy after 2-3 months. Initial dosing should start orally at a daily dose of 8mg loading dose followed by 4mg once a day. The dose should then be individualized over the next 2-3 months aiming for a sirolimus drug trough level of 5-12ng/ml. Ciclosporin doses should be tapered during this time to obtain a trough level of mg/ml. In the maintenance phase ciclosporin is progressively discontinued over 4-8 weeks and sirolimus dose is increased to give a drug trough level of 12-20ng/ml. Concurrent dosing with corticosteroids is required at this stage. Sirolimus is often swapped with ciclosporin or tacrolimus in cases of nephrotoxicity and there is no tapering of Ciclosporin dose. Supply Sirolimus is available as Rapamune tablets from Wyeth. Prescribing Sirolimus is classified on the traffic light system as an Amber 1 medication which means that it should only be prescribed under a shared care protocol with additional biochemical monitoring on a level 1 basis as per local enhanced service. Initiation of sirolimus treatment will be made by the hospital. The hospital will perform the relevant tests before treatment is started and will supply the first three months of medication. Once the patient is considered to be stable the specialists will write to the GP asking for agreement to take over the responsibility for prescribing, detailing dose information and monitoring requirements. Sirolimus is prescribable on FP10. Page 3 of 12
5 Adverse effects Very common Lymphocele, peripheral oedema, hypertension, headache, abdominal pain, diarrhoea, constipation, nausea, anaemia, thrombocytopenia, hypercholesterolaemia, hypertriglyceridaemia, hypophosphateaemia, hyperglycaemia, hypokalaemia, increased lactate dehydrogenase, arthralgia, acne, arthralgia, urinary tract infection. Common Abnormal healing, fever, oedema, fungal viral and bacterial infection, tachycardia, VTE, stomatitis, leucopenia, neutropenia, thrombotic thrombocytopenic purpura, abnormal liver function tests, bone necrosis, epistaxis, pneumonia, pneumonitis, skin cancer, rash, pyleonephritis, proteinuria. Uncommon Pancreatitis, lymphoma, post transplant lymphoproliferative disorder, pancytopenia, pulmonary haemorrhage. Rare Lymphodema, hypersensisitivity reactions, anaphylactic reactions, angioedma and vasculitis. Increased risk of malignancies including lymphoma, skin and other tumours appear to be linked to degree and duration of immunosuppression. The incidence is similar to other immunosuppressive agents or therapies. Patients should be counselled with regard to the risk of skin malignancy from exposure to UV light. Contraindications Hypersensitivity to the active substance or to any of the excipients. Patients allergic to peanut or soya must not take this medicine. Pregnancy exclude before starting if contraception is needed non-hormonal methods should be used). Breastfeeding. Precautions Monitor renal function if given in combination with ciclosporin Dose increases may be required in patients from Afro-Caribbean background Hepatic impairment monitor drug trough levels closely. Page 4 of 12
6 Drug Interactions Increased levels of sirolimus: Inhibitors of CYP3A4 decrease the metabolism and increase levels (e.g. diltiazem, verapamil, ketoconazole, voriconazole, clarithromycin) Weak inhibitors of CYP3A4 e.g. clotrimazole, fluconazole, cimetidine, danazol) Sirolimus plasma concentrations are increased by ciclosporin Decreased levels of sirolimus Inducers of CYP3A4 increase metabolism and decrease levels (e.g. rifampicin) Weak inducers of CYP3A4 (St John s Wort, carbamazepine, phenytoin) grapefruit juice should be avoided Pharmacokinetic interactions may also be observed with gastric prokinetic agents such as cisparide and metoclopramide Live vaccines should not be administered whilst taking CICLOSPORIN Monitoring Blood levels of sirolimus Electrolytes, creatinine and urea Full blood count and coagulation values Liver function tests Cholesterol testing Area of responsibility for the sharing of care Sharing of care assumes communication between the specialist, GP and the patient. The intention to share care should be explained to the patient and accepted by them. Officially the prescribing clinician has clinical responsibility for the medication they have prescribed. Page 5 of 12
7 Responsibilities of the hospital Initial tests and monitoring until patient is stable on therapy Discussion with the patient regarding benefits and side effects of treatment Provide the patient with verbal and written information prior to commencing treatment To seek the co-operation of the GP in undertaking shared care of the patient, in accordance with these guidelines and in the referral letter. The opportunity for the GP and hospital consultant to further discuss the case and shared care, if required will be highlighted To provide the patient s GP with a full summary letter indicating dose and frequency before implementation of shared care To provide the patient and GP with blood test results Monitoring of treatment including drug levels and renal function as agreed Prompt communication with the GP of any changes in treatment (including dose adjustments) and assessments of adverse events Advice to GPs about all aspects of treatment including specifying review dates Reporting adverse events to the CSM Ensure clear arrangements for back-up, advice and support Responsibilities of the General Practitioner To prescribe maintenance therapy to patients To report any adverse events to the consultant and CSM Prompt referral to specialist if there is any change in patient s status Reporting to and seeking advice from the specialist on any aspect of patient care which is of concern to the GP and may affect treatment To monitor overall health and well-being of the patient After stabilization to carry out blood tests, cholesterol tests (every 6 months) and monitor renal function at intervals directed by specialist Overdose Please always contact the poisons help line. UK National Poisons Information Service (directs caller to relevant local centre) and/or the Summary of Product Characteristics (SPC) of the sirolimus product (via Page 6 of 12
8 Availability of Consultant and senior hospital staff Consultant Dr A Chan Consultant Dr S Abeygunasekara Consultant Dr A Ali Renal Pharmacist Sarah Cox Additional sources of advice Pharmacy Medicines Information Broomfield Hospital (Mon-Fri 9-4) On Call Hospital Pharmacist On Call Nephrologist (bleep via switchboard) Useful sources of information BNF (current edition) MIMS SPC for mycophenolate (via Page 7 of 12
9 Initial Letter Appendix I Re: (drug name) shared care guidelines Patient s details Dear Dr I have seen this patient in clinic and believe that he/she is suitable for treatment with Drug name. I have initiated this patient on and will be prescribing and monitoring this patient at our clinics until such time that the patient is deemed stable, which is likely to be in the region of..months. I would like to seek your agreement to take over the prescribing and monitoring of this patient s treatment after this stabilisation period as per agreed shared care guidelines. A copy of the shared care guidelines is enclosed for your information. Please complete the form below and fax back to the stated safe haven fax numbers. I thank you in anticipation. Yours Sincerely Dr Consultant Enc Fax back to: Clinic/Hospital Fax PCT fax Delete as applicable I agree to take over prescribing and monitoring responsibility for this patient as per enclosed shared care guidelines from such date as the patient is deemed stable. I am not willing to undertake shared-care for this patient because. (Patient name: Hospital number: ) Yours sincerely Dr.. Page 8 of 12
10 Second letter to start shared care Appendix II Re: (drug name) shared care guidelines Patient s details Dear Dr Thank you for agreeing to shared care for the above named patient as per my initial letter dated. I have been prescribing and monitoring for this patient for the past stable as per agreed shared care guidelines. and the patient is deemed The patient is doing well and is currently on (details of dosage regimen). I would like to discharge this patient to you for prescribing and monitoring of the drug and the general well being of the patient within the parameters of the shared care. I have prescribed for this patient for a further 28 days. I will continue to see this patient in clinic annually to monitor disease progress. In the mean while if there is any thing that concerns you about the patient, please do not hesitate to contact me. Yours Sincerely Dr Consultant Page 9 of 12
11 To establish shared care in existing patients Appendix III Re: (drug name) shared care guidelines Patient s details Dear Dr You may already be prescribing (drug name) for the above mentioned patient. The patient is now deemed stable as per agreed shared care guidelines and is doing well. The patient is currently on (details of dosage regimen). I would like to discharge this patient to you for prescribing and monitoring of the drug and the general well being of the patient within the parameters of the shared care. I will continue to see this patient in clinic annually or as appropriate to monitor disease progress. In the mean while if there is any thing that concerns you about the patient, please do not hesitate to contact me. Yours Sincerely Dr Consultant cc. Dispensary Manager, Pharmacy Department, Broomfield Hospital Fax back to: Clinic/Hospital Fax PCT fax Delete as applicable I agree to take over prescribing and monitoring responsibility for this patient as per enclosed shared care guidelines from such date as the patient is deemed stable. I am not willing to undertake shared-care for this patient because. (Patient name: Hospital number: ) Yours sincerely Dr.. Name and address for the practice Page 10 of 12
12 Title Document reference Author Approved by Date approved September 2016 Next review date September 2019 Sirolimus Shared Care Guidelines Sarah Cox, Renal Pharmacist MEHT Clare Drain, Medicines Information & Education & Training manager, MEHT APC Previous Version May 2012 Key Changes Page 11 of 12
Basingstoke,Winchester and Southampton District Prescribing Committee. Shared Care Guideline: Sirolimus
Basingstoke,Winchester and Southampton District Prescribing Committee Shared Care Guideline: Sirolimus Name of patient treated under this guideline: This shared care guideline has been produced to support
More informationMycophenolate Mofetil (MMF)
SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in
More informationSCG: For Transplant patients AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE
SCG: For Transplant patients The following guidelines are designed to provide information relating to tacrolimus and to outline the responsibilities of the primary and secondary care teams in the prescribing
More informationShared Care Guidelines In partnership with Acute Trust & PCTs TACROLIMUS In renal transplant
Shared Care Guidelines In partnership with Acute Trust & PCTs TACROLIMUS In renal transplant August 2016 TacrolimusGUI201609V2.0FINAL Page 0 of 17 Table of Contents Introduction 2 Licensing 2 Referral
More informationTACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver disease
Oxford Gastroenterology Unit Shared Care Protocol & Information for GPs TACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver
More informationTacrolimus (Adoport, Prograf, Modigraf or Advagraf )
Shared Care Guideline DRUG: Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) for Renal Transplant (Adults) Introduction: Indication: Prophylaxis of transplant rejection in kidney recipients Tacrolimus
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationBasingstoke,Winchester and Southampton District Prescribing Committee. Shared Care Guideline: Prograf (Tacrolimus)
Basingstoke,Winchester and Southampton District Prescribing Committee Shared Care Guideline: Prograf (Tacrolimus) Name of patient treated under this guideline: This shared care guideline has been produced
More informationPRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)
PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of
More informationFulvestrant (Faslodex )
In Partnership with Health Authorities & GPs continuing-care guidelines Fulvestrant (Faslodex ) in the Management of Postmenopausal Women with Advanced Breast Cancer Approved by: Date approved: October
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationPrescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationSHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation in Adults
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation
More informationMYCOPHENOLATE MOFETIL In Renal Transplantation (prior to August 2004) and lupus nephritis/vasculitis
Patient name Date of Birth DOCUMENT TO BE FILED IN NOTES AND SCANNED INTO ELECTRONIC RECORDS INTRODUCTION Mycophenolate Mofetil (Cellcept ) * is currently used first line as part of the triple immunosuppressant
More informationSHARED CARE PRESCRIBING GUIDELINE
SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationPrescribing Framework for Ciclosporin Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Ciclosporin Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationBreast Pathway Group Everolimus in Advanced Breast Cancer
Breast Pathway Group Everolimus in Advanced Breast Cancer Indication: Hormone receptor positive, HER2 negative advanced breast cancer National Cancer Drug Fund criteria: ER+ve, HER2 ve metastatic breast
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationDegarelix Subcutaneous Injection (Firmagon ) Treatment Guideline
Mid Essex Locality Degarelix Subcutaneous Injection (Firmagon ) Treatment Guideline Contents FlowChart 2 Summary... 3 Key points... 3 Introduction... 3 Pharmacology... 3 Product information... 4 Place
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 5 1. NAME OF THE MEDICINAL PRODUCT Rapamune 1 mg/ml oral solution. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 1 mg sirolimus. For excipients,
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: CICLOSPORIN Protocol number: CV 06
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: CICLOSPORIN Protocol number: CV 06 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS
More informationSunitinib (renal) ICD-10 codes Codes with a prefix C64
Sunitinib (renal) Indication First line treatment of patients with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG)
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationSirolimus 1mg/1ml oral solution
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Sirolimus 1mg/1ml oral solution You should read this information sheet in conjunction with any patient information
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationShared care guidelines for azathioprine in adults. General principles. Presentation/Dose/Administration Oral: 25mg and 50mg tablets
Shared care guidelines for azathioprine in adults General principles This agreement outlines suggested ways in which the responsibilities for managing the prescribing of the drug treatment and clinical
More informationIBRUTINIB (IMBRUVICA ) for Chronic Lymphocytic Leukaemia. and Mantel Cell Lymphoma
DRUG ADMINISTRATION SCHEDULE Indication Cycle Length Drug Daily Dose Route Schedule Chronic Lymphocytic Leukaemia Continuous Ibrutinib 420mg (three capsules) Oral ONCE daily Mantel Cell Lymphoma Continuous
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationAREAS OF RESPONSIBILITY FOR THE SHARING OF CARE
Effective Shared Care Agreement (ESCA) Midodrine ESCA: For the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: TACROLIMUS Protocol number: CV 43
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: TACROLIMUS Protocol number: CV 43 Indications: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION IN ADULTS.
More informationShared Care Guideline: Leflunomide
Basingstoke, Winchester & Southampton District Prescribing Committee Shared Care Guideline: Leflunomide Name of patient treated under this guideline: This shared care guideline has been produced to support
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationCiclosporin for Rheumatology and Dermatology use (Adults)
Shared Care Guideline Ciclosporin for Rheumatology and Dermatology use (Adults) Introduction This shared care agreement outlines the responsibilities between the specialist and the generalist for managing
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationShared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults
Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:
More informationShared Care Guideline Metolazone for fluid management in CKD (Adults)
Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationPRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis
PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics
More informationDorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )
INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationTREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals.
BOSUTINIB INDICATION Licensed / NICE TA401 (BLUETEQ required) The treatment of adult patients with chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML)
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationEssential Shared Care Agreement Naltrexone
In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationEFFECTIVE SHARED CARE AGREEMENT. July Dronedarone (Multaq ) For the treatment and management of atrial fibrillation
Whipps Cross University Hospital NHS Trust EFFECTIVE SHARED CARE AGREEMENT July 2011 Dronedarone (Multaq ) For the treatment and management of atrial fibrillation INTRODUCTION The Whipps Cross University
More informationCabozantinib (Cabometyx )
Cabozantinib (Cabometyx ) Indication Treatment of advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF) targeted therapy. (NICE TA463) Treatment of previously untreated
More informationShared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients
Shared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients Specialist Details Name: Patient Identifier (please include NHS number as minimum) Location: Telephone
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationMedicines Management Group
SHARED CARE PROTOCOL for FULVESTRANT (FASLODEX ) INJECTION Scope Fulvestrant may be considered for shared care arrangements for the treatment of metastatic breast cancer for disease relapse. Unique Identifier
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More informationEffective Shared Care Agreement (ESCA)
Effective Shared Care Agreement (ESCA) Azathioprine (either alone or more usually in combination with corticosteroids and/or other drugs and procedures) ESCA: For the treatment of systemic lupus erythematosus
More informationPlease complete all sections 1. Name of Drug, Brand Name, Form and Strength
GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline Ciclosporin for use in childhood nephrotic syndrome Reference Number Replaces: n/a Issue date: 15/10/2015 Author(s)/Originator(s):
More informationNHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE
Suffolk Drug & Therapeutics Committee NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE What is a shared care document? Suffolk D&T operates a traffic light
More informationLymphangioleiomyomatosis Patients:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RAPAMUNE safely and effectively. See full prescribing information for RAPAMUNE. RAPAMUNE (sirolimus)
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationSOMATROPIN ( Genotropin, Humatrope, Norditropin,
Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300
More informationPatient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services
Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationWARNING: MALIGNANCIES AND SERIOUS INFECTIONS,
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZORTRESS safely and effectively. See full prescribing information for ZORTRESS. ZORTRESS (everolimus)
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationEFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation
EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationSHARED CARE GUIDELINE For
SHARED CARE GUIDELINE For Leuprorelin (Prostap 3 DCS ) for advanced hormone dependent prostate cancer Implementation Date: Review Date: This guidance has been prepared and approved for use within Gateshead,
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationEFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP.
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. The aim of an Effective Shared Care Agreement
More informationThis guideline is under review. Please continue to use this version until the review has been completed
This guideline is under review. Please continue to use this version until the review has been completed SHARED CARE PRESCRIBING GUIDELINE Continuation of Advagraf (tacrolimus modified release {MR}) for
More informationFACTSHEET CICLOSPORIN. Introduction. How does ciclosporin work? When is ciclosporin used?
Introduction Ciclosporin is a potent immunosuppressant drug that requires supervision by a specialised doctor such as a dermatologist. It was originally used to prevent organ rejection in transplant patients.
More informationEdoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF
Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rapamune 1 mg/ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 1 mg sirolimus. Each 60 ml bottle
More informationTEMSIROLIMUS in renal cell cancer
Systemic Anti Cancer Treatment Protocol TEMSIROLIMUS in renal cell cancer PROTOCOL REF: MPHARTEMS (Version No: 1.0) Approved for use in: First-line treatment of adult patients with advanced renal cell
More informationShared care guidelines for hydroxychloroquine for rheumatoid arthritis and other rheumatological conditions in adults.
Shared care guidelines for hydroxychloroquine for rheumatoid arthritis and other rheumatological conditions in adults. General Principles This agreement outlines suggested ways in which the responsibilities
More information1. and it is more than 12 hours until your next dose, take the missed dose and continue with your normal schedule
Everolimus Everolimus (Afinitor ) for pancreatic neuroendocrine tumours This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy
More informationZYDELIG PBS. (idelalisib) RETHINK WHAT S POSSIBLE... LISTED 1
RETHINK WHAT S POSSIBLE... ZYDELIG (idelalisib) PBS LISTED 1 st 1 September 2017 ZYDELIG a first-in-class oral PI3Kδ inhibitor is PBS listed from 1 st September 2017 for the treatment of: Double-refractory
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: HYDROXYCHLOROQUINE INDICATION/S COVERED: active rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus Coastal West
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationPazopanib in Renal cell carcinoma
REGIMEN TITLE: Pazopanib in Renal cell carcinoma Page 1 of 5 Indication: Notes: First line treatment option in advanced renal cell carcinoma Patients who have not received prior cytokine therapy Eastern
More informationSHARED CARE GUIDELINE FOR MYCOPHENOLATE MOFETIL FOR RHEUMATOLOGY INDICATIONS 1. Aim/Purpose of this Guideline
SHARED CARE GUIDELINE FOR MYCOPHENOLATE MOFETIL FOR RHEUMATOLOGY INDICATIONS 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate
More informationS H A R E D P R E S C R I B I N G G U I D E L I N E
S H A R E D P R E S C R I B I N G G U I D E L I N E Introduction This shared prescribing guideline for the second generation antipsychotic medications listed above has been developed with due consideration
More informationPackage leaflet: Information for the user. Rapamune 1 mg/ml oral solution sirolimus
Package leaflet: Information for the user Rapamune 1 mg/ml oral solution sirolimus Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationSHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty
WORKING IN PARTNERSHIP WITH SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR 11.25 mg TM ) for precocious puberty NHS Surrey s Medicines Management Committee classification:
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Tacrolimus for Maintenance of Immunosuppression after Kidney Transplantation in Adults This protocol cover
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More information